Placenta
Volume 30, Issue 12 , Pages 1065-1070 , December 2009

Therapeutic Effects of Anticoagulant Agents on Preeclampsia in a Murine Model Induced by Phosphatidylserine/Phosphatidylcholine Microvesicles

  • Y. Zhang

      Affiliations

    • Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    • ,
  • Z. Hua

      Affiliations

    • State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, China
    • ,
  • K. Zhang

      Affiliations

    • Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    • ,
  • K. Meng

      Affiliations

    • Department of Pathology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    • ,
  • Y. Hu

      Affiliations

    • Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    • Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, 321 Zhongshan Road, Nanjing 210008, China. Tel.: +86 25 8332 1980.

,Accepted 17 September 2009.

References 

  1. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38:718–722
  2. McCoy S, Baldwin K. Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009;66:337–344
  3. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta. 2009;30:S43–S48
  4. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294:H541–H550
  5. Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth restriction. J Clin Pathol. 2008;61:1254–1260
  6. Vinnars MT, Wijnaendts LC, Westgren M, Bolte AC, Papadogiannakis N, Nasiell J. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension. 2008;51:1295–1299
  7. Hawfield A, Freedman BI. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis. 2009;3:65–73
  8. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta. 2002;23:337–342
  9. Peracoli MT, Menegon FT, Borges VT, de Araujo Costa RA, Thomazini-Santos IA, Peracoli JC. Platelet aggregation and TGF-beta (1) plasma levels in pregnant women with preeclampsia. J Reprod Immunol. 2008;79:79–84
  10. Walker ID. Thrombophilia in pregnancy. J Clin Pathol. 2000;53:573–580
  11. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  12. Omatsu K, Kobayashi T, Murakami Y, Suzuki M, Ohashi R, Sugimura M, et al. Phosphatidylserine/phosphatidylcholine microvesicles can induce preeclampsia-like changes in pregnant mice. Semin Thromb Hemost. 2005;31:314–320
  13. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta. 2008;1783:953–963
  14. Masuda J, Takayama E, Satoh A, Ida M, Shinohara T, Kojima-Aikawa K, et al. Levels of annexin IV and V in the plasma of pregnant and postpartum women. Thromb Haemost. 2004;91:1129–1136
  15. Rand JH, Wu XX, Guller S, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med. 1997;337:154–160
  16. Zhang LN, Yang X, Hua ZC. Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000;30:305–312
  17. Yuan H, Yang X, Hua ZC. Optimization of expression of an annexin V-hirudin chimeric protein in Escherichia coli. Microbiol Res. 2004;159:147–156
  18. Ju CW, W Ls Yang X, Ma GS, Hua ZC, Gao XY. A study of human annexin V derivate: its effect of anticoagulation and antithrombosis. Zhonghua Xue Ye Xue Za Zhi. 2004;25:540–543
  19. Fan Y, Wang J, Yang S, Yang X. Molecular dynamics simulation of docking a novel hirudin-like anti-coagulant protein to thrombin. Prog Biochem Biophy. 2001;28:86–89
  20. Saisto T, Tiitinen A, Ulander VM, Kaaja R. Clinical cure of severe, early onset preeclampsia with low olecular weight heparin therapy in primigravida with hyperreactio luteinas and thrombophilia. Hum Reprod. 2004;19:725–728
  21. Urban G, Vergani P, Tironi R, Ceruti P, Vertemati E, Sala F, et al. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med. 2007;52:59–67
  22. Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007;29:787–793
  23. Li X, Gao FL, Wang F, He Y, Sun SH. Construction of recombinant plasmid pEGFP-anxA5 and its expression in Hela cells. Chin J Anat. 2006;29:443–445
  24. Xu D, Wu Y, Liao ZX, Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res. 2007;55:280–286
  25. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19:1288–1296
  26. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol. 2004;191:412–424
  27. Tanjung MT, Siddik HD, Hariman H, Koh SC. Coagulation and fibrinolysis in preeclampsis and neonates. Clin Appl Thromb Hemost. 2005;11:467–473
  28. Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost. 2007;13:285–291
  29. Irminger-Finger I, Jastrow N, Irion O. Preeclampsia: a danger growing in disguise. Int J Biochem Cell Biol. 2008;40:1979–1983
  30. Lyden TW, Ng AK, Rote NS. Modulation of phosphatidylserine epitope expression by BeWo cells during forskolin treatment. Placenta. 1993;14:177–186
  31. Rote NS, Chang J, Katsuragawa H, Ng AK, Lyden TW, Mori T. Expression of phosphatidylserine-dependent antigens on the surface of differentiating BeWo human choriocarcinoma cells. Am J Reprod Immunol. 1995;33:114–121
  32. Krikun G, Lockwood CJ, Wu XX, Zhou XD, Guller S, Calandri C, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta. 1994;15:601–612
  33. Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest. 2000;49:17–23
  34. Sugimura M, Kobayashi T, Shu F, Kanayama N, Terao T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice. Placenta. 1999;20:555–560
  35. Nowak G, Schror K. Hirudin—the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. Thromb Haemost. 2007;98:116–119

PII: S0143-4004(09)00300-2

doi: 10.1016/j.placenta.2009.09.004

Placenta
Volume 30, Issue 12 , Pages 1065-1070 , December 2009

Article Tools

* Image Usage & Resolution